|
Scilex Holding Company (NASDAQ: SCLX) |
|
Scilex Holding Company
SCLX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Scilex Holding growth rates, revenue grew
by 30.11 % in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3285
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.07 %
Scilex Holding net loss increased from $-27 millions, to $-38 millions in II. Quarter 2024,
• More on SCLX's Growth
|
|
Scilex Holding realized a net loss in trailing twelve months.
Scilex Holding realized cash reduction of $ -0.21 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.19.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.38.
• More on SCLX's Valuation
|
|
|
|
|
Scilex Holding realized net loss in trailing twelve months.
Scilex Holding realized cash outflow of $ -0.21per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.19.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.38.
• More on SCLX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com